The condition comprises a heterogeneous collection of disorders unified by a shared underlying pathology of thrombotic microangiopathy, which is classically defined by the concurrent presence of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury [2].
Disease overview
OtherHaemolytic uraemic syndrome (HUS)
溶血性尿毒综合征
Evidence-backed informationEN 3/7 applicable sections · ZH 3/7 applicable sectionsUpdated Sep 3, 2026
Haemolytic uraemic syndrome represents a clinically significant condition frequently associated with Shiga toxin-producing Escherichia coli infections, drawing international attention due to transcontinental outbreak potential and notable mortality rates [1][2]. Diagnostic advancements have substantially increased case identification over recent decades, revealing a broad spectrum of bacterial subtypes capable of triggering the syndrome [3].
Read the full clinical and epidemiological profile4
Clinical presentation is classically characterized by the triad of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury [2].
Non-O157:H7 STEC-driven outbreaks have attracted considerable focus due to their capacity to cross borders and cause fatal outcomes, with incidence patterns differing markedly between developed and developing regions [1]. Longitudinal monitoring indicates a steady rise in diagnosed cases over recent years, with particular toxin subtypes consistently linked to syndrome progression [3].
- 1Purwar S et al. Non-O157:H7 Shiga Toxin Producing Diarrhoeagenic Escherichia coli (STEC) in Southern India: A Tinderbox for Starting Epidemic. J Clin Diagn Res. 2016 Oct. PMID: 27891338. doi: 10.7860/JCDR/2016/21462.8714.PubMed: https://pubmed.ncbi.nlm.nih.gov/27891338/
- 2Michael M et al. Haemolytic uraemic syndrome. Lancet. 2022 Nov 12. PMID: 36272423. doi: 10.1016/S0140-6736(22)01202-8.PubMed: https://pubmed.ncbi.nlm.nih.gov/36272423/
- 3Scheutz F et al. Shiga Toxin-Producing E. coli (STEC) from Danish Patients, 1997-2023: Diagnostic Trends and Bacteriological Findings. Microorganisms. 2025 Oct 12. PMID: 41156801. doi: 10.3390/microorganisms13102342.PubMed: https://pubmed.ncbi.nlm.nih.gov/41156801/
Coverage
Reporting countries and regions
Trends by reporting country
Monthly patterns over time
Data access
Page dataset index with source links and update metadata.
Official sourcesAuthority, cadence, notes9
Australia NINDSS
Australia
Australian national notifiable diseases surveillance dashboard.
Australia NINDSS — Australian Capital Territory
Australian Capital Territory, Australia
Australian NINDSS monthly state/territory notifications for Australian Capital Territory, kept separate from the Australia national aggregate.
Australia NINDSS — New South Wales
New South Wales, Australia
Australian NINDSS monthly state/territory notifications for New South Wales, kept separate from the Australia national aggregate.
Australia NINDSS — Northern Territory
Northern Territory, Australia
Australian NINDSS monthly state/territory notifications for Northern Territory, kept separate from the Australia national aggregate.
Australia NINDSS — Queensland
Queensland, Australia
Australian NINDSS monthly state/territory notifications for Queensland, kept separate from the Australia national aggregate.
Australia NINDSS — South Australia
South Australia, Australia
Australian NINDSS monthly state/territory notifications for South Australia, kept separate from the Australia national aggregate.
Australia NINDSS — Tasmania
Tasmania, Australia
Australian NINDSS monthly state/territory notifications for Tasmania, kept separate from the Australia national aggregate.
Australia NINDSS — Victoria
Victoria, Australia
Australian NINDSS monthly state/territory notifications for Victoria, kept separate from the Australia national aggregate.
Australia NINDSS — Western Australia
Western Australia, Australia
Australian NINDSS monthly state/territory notifications for Western Australia, kept separate from the Australia national aggregate.